A detailed history of China Universal Asset Management Co., Ltd. transactions in Bio N Tech Se stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 18,700 shares of BNTX stock, worth $1.49 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
18,700
Previous 18,700 -0.0%
Holding current value
$1.49 Million
Previous $1.73 Million -0.0%
% of portfolio
0.22%
Previous 0.22%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$88.96 - $112.35 $666,132 - $841,276
7,488 Added 66.79%
18,700 $1.73 Million
Q4 2023

May 21, 2024

SELL
$90.91 - $112.75 $680,734 - $844,272
-7,488 Reduced 40.04%
11,212 $1.18 Million
Q4 2023

Jan 23, 2024

BUY
$90.91 - $112.75 $793,735 - $984,420
8,731 Added 351.91%
11,212 $1.18 Million
Q3 2023

May 21, 2024

BUY
$98.5 - $125.08 $31,224 - $39,650
317 Added 14.65%
2,481 $269,000
Q3 2023

Oct 30, 2023

BUY
$98.5 - $125.08 $31,224 - $39,650
317 Added 14.65%
2,481 $270,000
Q2 2023

May 21, 2024

SELL
$102.58 - $129.66 $4,205 - $5,316
-41 Reduced 1.86%
2,164 $233,000
Q2 2023

Jul 27, 2023

SELL
$102.58 - $129.66 $4,205 - $5,316
-41 Reduced 1.86%
2,164 $234,000
Q1 2023

May 21, 2024

SELL
$122.57 - $153.67 $2.07 Million - $2.59 Million
-16,860 Reduced 88.43%
2,205 $274,000
Q1 2023

Apr 27, 2023

SELL
$122.57 - $153.67 $2.07 Million - $2.59 Million
-16,860 Reduced 88.43%
2,205 $275,000
Q4 2022

May 21, 2024

BUY
$118.43 - $186.05 $43,226 - $67,908
365 Added 1.95%
19,065 $2.86 Million
Q4 2022

Jan 31, 2023

BUY
$118.43 - $186.05 $2.16 Million - $3.39 Million
18,240 Added 2210.91%
19,065 $2.86 Million
Q3 2022

Oct 21, 2022

SELL
$127.65 - $183.11 $188,028 - $269,721
-1,473 Reduced 64.1%
825 $111,000
Q4 2021

Feb 11, 2022

BUY
$216.64 - $362.52 $497,838 - $833,070
2,298 New
2,298 $592,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $19.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.